VCYT
VERACYTE, INC.
+1.15 (+2.97%)39.65USD408K成交股數3.2B市值28.3本益比(近四季)5.7股價營收比+15.5%營收年增(近四季)2026-11-03下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 150M+31% | 139M+17% | 132M+14% | 130M+14% | 114M+18% | 119M+32% | 116M+28% | 114M+39% | 96.8M | 90.1M | 90.3M | 82.4M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | 109M+37% | 101M+28% | 91.3M+16% | 89.8M+15% | 79.5M+27% | 78.8M+37% | 79.0M+42% | 77.9M | 62.5M | 57.7M | 55.8M | – |
| 毛利率 | 72.2% | 72.7% | 69.2% | 69.0% | 69.5% | 66.4% | 68.2% | 68.1% | 64.5% | 64.0% | 61.8% | – |
| 研發費用 | 29.4M | 27.1M | 16.0M | 16.3M | 17.7M | 19.3M | 17.6M | 16.5M | 16.0M | 13.3M | 12.5M | 12.8M |
| 銷售管理費用 | 27.4M | 23.7M | 27.3M | 32.3M | 33.8M | 26.9M | 25.7M | 31.7M | 26.2M | 16.3M | 25.0M | 21.1M |
| 營業利益 | 23.0M+691% | 22.6M+442% | 22.9M+91% | −5.3M-214% | 2.9M-162% | 4.2M-113% | 12.0M-249% | 4.6M-144% | −4.7M | −31.7M | −8.1M | −10.5M |
| 營業利益率 | 15.3% | 16.3% | 17.4% | -4.0% | 2.5% | 3.5% | 10.4% | 4.0% | -4.8% | -35.2% | -8.9% | -12.7% |
| 稅後淨利 | 25.5M+262% | 28.7M+466% | 19.1M+26% | −980K-117% | 7.0M-478% | 5.1M-117% | 15.2M-280% | 5.7M-171% | −1.9M | −29.6M | −8.4M | −8.1M |
| 淨利率 | 17.0% | 20.6% | 14.5% | -0.8% | 6.2% | 4.3% | 13.1% | 5.0% | -1.9% | -32.9% | -9.3% | -9.8% |
| 稀釋 EPS | 0.31+244% | 0.35+400% | 0.24+26% | -0.01-114% | 0.09-550% | 0.07-117% | 0.19-258% | 0.07-164% | -0.02 | -0.41 | -0.12 | -0.11 |
| 稀釋股數 | 82.1M | 81.3M | 79.7M | 78.4M | 80.1M | 78.2M | 78.5M | 77.2M | 74.8M | 72.8M | 72.5M | 72.2M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 300M | 263M | 316M | 219M | 186M | 239M | 274M | 236M | 209M | 202M | 191M | 178M |
| 應收帳款 | 54.2M | 50.1M | 47.8M | 50.8M | 53.8M | 46.5M | 48.8M | 50.3M | 46.7M | 39.3M | 42.4M | 45.5M |
| 存貨 | – | – | 20.3M | 25.0M | 24.3M | 21.8M | 20.4M | 19.3M | 18.3M | 15.9M | 11.6M | 13.3M |
| 總資產 | 1.5B | 1.4B | 1.4B | 1.3B | 1.3B | 1.3B | 1.3B | 1.2B | 1.2B | 1.1B | 1.2B | 1.2B |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 98.0M | 92.0M | 110M | 123M | 120M | 124M | 99.0M | 102M | 81.4M | 70.9M | 78.4M | 75.9M |
| 股東權益 | 1.4B | 1.3B | 1.3B | 1.2B | 1.2B | 1.2B | 1.2B | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B |
| 負債比 | 6.6% | 6.4% | 8.1% | 9.2% | 9.2% | 9.5% | 7.8% | 8.2% | 6.8% | 6.3% | 6.8% | 6.6% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 35.2M | – | – | 5.4M-160% | – | – | – | −9.0M | – | – | −2.2M |
| 資本支出 | – | 3.0M | – | – | 1.8M | – | – | – | 2.1M | – | – | 993K |
| 自由現金流 | – | 32.3M | – | – | 3.5M-132% | – | – | – | −11.1M | – | – | −3.2M |
| 折舊攤銷 | – | 5.4M | – | – | 5.4M | – | – | – | 5.6M | – | – | 6.7M |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 23.2% | – | – | 3.1% | – | – | – | -11.5% | – | – | -3.8% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 517M
| Reportable | 517M | 100.0% | +16.0% |
|---|
地區2025 年度 · 517M
| 美國 | 497M | 96.0% | +17.3% |
|---|---|---|---|
| 美國以外 | 20.5M | 4.0% | -7.6% |
產品／服務2025 年度 · 523M
| Testing | 493M | 94.2% | +17.7% |
|---|---|---|---|
| 產品 | 14.3M | 2.7% | +5.0% |
| Biopharmaceutical And Other Biopharmaceutical Revenue | 6.5M | 1.2% | -8.6% |
| Testing Other | 6.2M | 1.2% | -47.5% |
| Biopharmaceutical And Other Contract Manufacturing And Testing | 3.1M | 0.6% | -47.9% |
| Biopharmaceutical And Other 小計 | 9.7M | 1.8% | -26.5% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 517M | +16.0% | 66.4M | 12.8% | 0.82 | 127M |
| FY2024 | 446M | +23.5% | 24.1M | 5.4% | 0.31 | 63.8M |
| FY2023 | 361M | +21.8% | −74.4M | -20.6% | -1.02 | 34.3M |
| FY2022 | 297M | +35.1% | −36.6M | -12.3% | -0.51 | −1.0M |
| FY2021 | 220M | +86.8% | −75.6M | -34.4% | -1.11 | −37.0M |
| FY2020 | 117M | -2.4% | −34.9M | -29.7% | -0.66 | −12.5M |
| FY2019 | 120M | +30.8% | −12.6M | -10.5% | -0.27 | −6.0M |
| FY2018 | 92.0M | – | −23.0M | -25.0% | -0.62 | −15.4M |